Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Kyverna Therapeutics (Nasdaq: KYTX), a clinical-stage biopharmaceutical company specializing in cell therapies for autoimmune diseases, has announced its upcoming participation in the Leerink Partners Global Biopharma Conference.
The company's CEO, Warner Biddle, is scheduled to present at the conference in Miami, FL on Monday, March 10, 2025, at 3:00 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the Investors section of Kyverna's website at ir.kyvernatx.com. The presentation recording will remain available for replay on the website for 30 days after the conference.
Kyverna Therapeutics (Nasdaq: KYTX), un'azienda biofarmaceutica in fase clinica specializzata in terapie cellulari per le malattie autoimmuni, ha annunciato la sua prossima partecipazione alla Conferenza Globale Biopharma di Leerink Partners.
Il CEO dell'azienda, Warner Biddle, è programmato per presentare alla conferenza a Miami, FL, lunedì 10 marzo 2025, alle 15:00 ET. Gli investitori e le parti interessate possono accedere a una diretta streaming della presentazione attraverso la sezione Investitori del sito web di Kyverna all'indirizzo ir.kyvernatx.com. La registrazione della presentazione rimarrà disponibile per la riproduzione sul sito per 30 giorni dopo la conferenza.
Kyverna Therapeutics (Nasdaq: KYTX), una empresa biofarmacéutica en etapa clínica especializada en terapias celulares para enfermedades autoinmunes, ha anunciado su próxima participación en la Conferencia Global Biopharma de Leerink Partners.
El CEO de la empresa, Warner Biddle, está programado para presentar en la conferencia en Miami, FL, el lunes 10 de marzo de 2025, a las 3:00 p.m. ET. Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de Inversores en el sitio web de Kyverna en ir.kyvernatx.com. La grabación de la presentación estará disponible para su reproducción en el sitio durante 30 días después de la conferencia.
Kyverna Therapeutics (Nasdaq: KYTX), 자가면역 질환을 위한 세포 치료제에 특화된 임상 단계의 생물 의약품 회사가 Leerink Partners 글로벌 생물 의약품 회의에 참가할 예정이라고 발표했습니다.
회사의 CEO인 Warner Biddle은 2025년 3월 10일 월요일 오후 3시 ET에 플로리다주 마이애미에서 열리는 회의에서 발표할 예정입니다. 투자자 및 관심 있는 분들은 Kyverna의 웹사이트 ir.kyvernatx.com의 투자자 섹션을 통해 발표의 라이브 웹캐스트에 접근할 수 있습니다. 발표 녹화는 회의 후 30일 동안 웹사이트에서 재생할 수 있습니다.
Kyverna Therapeutics (Nasdaq: KYTX), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies cellulaires pour les maladies auto-immunes, a annoncé sa prochaine participation à la Conférence Biopharma Mondiale de Leerink Partners.
Le PDG de l'entreprise, Warner Biddle, est prévu pour présenter lors de la conférence à Miami, FL, le lundi 10 mars 2025, à 15h00 ET. Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section Investisseurs du site web de Kyverna à l'adresse ir.kyvernatx.com. L'enregistrement de la présentation restera disponible en replay sur le site pendant 30 jours après la conférence.
Kyverna Therapeutics (Nasdaq: KYTX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Zelltherapien für Autoimmunerkrankungen spezialisiert hat, hat seine bevorstehende Teilnahme an der Leerink Partners Global Biopharma Conference angekündigt.
Der CEO des Unternehmens, Warner Biddle, wird am Montag, den 10. März 2025, um 15:00 Uhr ET auf der Konferenz in Miami, FL präsentieren. Investoren und Interessierte können über den Bereich für Investoren auf der Website von Kyverna unter ir.kyvernatx.com auf einen Live-Stream der Präsentation zugreifen. Die Aufzeichnung der Präsentation bleibt 30 Tage nach der Konferenz auf der Website verfügbar.
- None.
- None.
A live webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for 30 days following the conference.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating patients through the curative potential of cell therapy. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase 2 trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase 1/2 trials for patients with lupus nephritis. Kyverna is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for it to advance into late-stage development. Its pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. For more information, please visit https://kyvernatx.com.
Contact:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/kyverna-therapeutics-to-present-at-the-leerink-partners-global-biopharma-conference-302390580.html
SOURCE Kyverna Therapeutics
FAQ
When is Kyverna Therapeutics (KYTX) presenting at the Leerink Partners Conference 2025?
How can investors watch Kyverna's (KYTX) Leerink Partners Conference presentation?
How long will Kyverna's (KYTX) Leerink Conference presentation be available for replay?
What is the main focus of Kyverna Therapeutics (KYTX)?
